DE69219217T2 - Neue 16-Methyl substituierte Steroidderivate von Pregna-1,4-dien-3,20-dion, ihre Herstellung, ihre Verwendung zur Herstellung von 16-Methylene-substituierte Steroide und neue Zwischenprodukten dafür - Google Patents

Neue 16-Methyl substituierte Steroidderivate von Pregna-1,4-dien-3,20-dion, ihre Herstellung, ihre Verwendung zur Herstellung von 16-Methylene-substituierte Steroide und neue Zwischenprodukten dafür

Info

Publication number
DE69219217T2
DE69219217T2 DE69219217T DE69219217T DE69219217T2 DE 69219217 T2 DE69219217 T2 DE 69219217T2 DE 69219217 T DE69219217 T DE 69219217T DE 69219217 T DE69219217 T DE 69219217T DE 69219217 T2 DE69219217 T2 DE 69219217T2
Authority
DE
Germany
Prior art keywords
preparation
new
pregna
dione
diene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69219217T
Other languages
English (en)
Other versions
DE69219217D1 (de
Inventor
Jean Boivin
Christine Chauvet
Samir Zard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of DE69219217D1 publication Critical patent/DE69219217D1/de
Publication of DE69219217T2 publication Critical patent/DE69219217T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0084Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkylene group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69219217T 1991-06-25 1992-06-24 Neue 16-Methyl substituierte Steroidderivate von Pregna-1,4-dien-3,20-dion, ihre Herstellung, ihre Verwendung zur Herstellung von 16-Methylene-substituierte Steroide und neue Zwischenprodukten dafür Expired - Lifetime DE69219217T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9107784A FR2678275B1 (fr) 1991-06-25 1991-06-25 Nouveaux sterouides 16-methyl substitue derives de la pregna 1,4-diene 3,20-dione leur preparation, leur application a la preparation de sterouides 16-methylene et nouveaux intermediaires.
CN92105005A CN1035948C (zh) 1991-06-25 1992-06-25 孕甾-1,4-二烯-3,20-二酮衍生物的制备方法

Publications (2)

Publication Number Publication Date
DE69219217D1 DE69219217D1 (de) 1997-05-28
DE69219217T2 true DE69219217T2 (de) 1997-11-13

Family

ID=36781528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69219217T Expired - Lifetime DE69219217T2 (de) 1991-06-25 1992-06-24 Neue 16-Methyl substituierte Steroidderivate von Pregna-1,4-dien-3,20-dion, ihre Herstellung, ihre Verwendung zur Herstellung von 16-Methylene-substituierte Steroide und neue Zwischenprodukten dafür

Country Status (17)

Country Link
US (1) US5248773A (de)
EP (1) EP0520879B1 (de)
JP (1) JP3037508B2 (de)
KR (1) KR100220540B1 (de)
CN (1) CN1035948C (de)
AT (1) ATE152119T1 (de)
AU (1) AU646342B2 (de)
CA (1) CA2072053C (de)
DE (1) DE69219217T2 (de)
DK (1) DK0520879T3 (de)
ES (1) ES2100315T3 (de)
FR (1) FR2678275B1 (de)
GR (1) GR3023294T3 (de)
HU (1) HU213674B (de)
MX (1) MX9202972A (de)
RU (1) RU2099346C1 (de)
ZA (1) ZA924665B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226413B1 (en) * 1991-06-25 2008-11-28 Aventis Pharma Sa Novel 16-(nitro-substituted methyl)pregna-1,4-dien-3,20-dion derivatives and process for producing them
FR2692266B1 (fr) * 1992-06-11 1994-08-05 Roussel Uclaf Nouveau procede de preparation de sterouides 16 alpha-methyles.
CN1061984C (zh) * 1996-04-18 2001-02-14 上海华联制药有限公司 甾体激素化合物中引入9-11双键的一种方法
KR101701404B1 (ko) * 2008-05-28 2017-02-01 레베라겐 바이오파마 인코포레이티드 질환의 치료를 위한 NF-κB 의 비호르몬성 스테로이드 조절제
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179496A1 (de) * 1982-09-20 1986-04-30 The Upjohn Company 16-Sulfinylmethylsteroide, ihre Herstellung und Anwendung
DE3484464D1 (de) * 1984-01-05 1991-05-23 Upjohn Co Stabilisiertes monolithiumacetylid und ethinylierung von steroiden.

Also Published As

Publication number Publication date
FR2678275A1 (fr) 1992-12-31
RU2099346C1 (ru) 1997-12-20
JP3037508B2 (ja) 2000-04-24
EP0520879B1 (de) 1997-04-23
EP0520879A3 (de) 1995-04-12
AU1847892A (en) 1993-01-07
GR3023294T3 (en) 1997-07-30
MX9202972A (es) 1993-04-01
KR100220540B1 (ko) 1999-10-01
FR2678275B1 (fr) 1995-06-23
KR930000534A (ko) 1993-01-15
US5248773A (en) 1993-09-28
EP0520879A2 (de) 1992-12-30
DE69219217D1 (de) 1997-05-28
CN1035948C (zh) 1997-09-24
CA2072053A1 (fr) 1992-12-26
DK0520879T3 (da) 1997-10-20
AU646342B2 (en) 1994-02-17
HUT61569A (en) 1993-01-28
ZA924665B (en) 1993-06-24
HU9202100D0 (en) 1992-10-28
HU213674B (en) 1997-09-29
CA2072053C (fr) 2003-10-21
JPH05186496A (ja) 1993-07-27
ES2100315T3 (es) 1997-06-16
CN1068120A (zh) 1993-01-20
ATE152119T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
ATE284895T1 (de) Neuroaktive steroide der androstan- und pregnanreihe
KR890000761B1 (ko) 스테로이드의 방향성 헤테로사이클릭 에스테르 및 이의 제조방법
DE69205405D1 (de) 17-Spirofuran-3'-Yliden Steroide.
DE69219217D1 (de) Neue 16-Methyl substituierte Steroidderivate von Pregna-1,4-dien-3,20-dion, ihre Herstellung, ihre Verwendung zur Herstellung von 16-Methylene-substituierte Steroide und neue Zwischenprodukten dafür
NO842408L (no) Fremgangsmaate ved fremstilling av 1-alkyl-androsta-1,4-dien-3,17-dioner
KR890701612A (ko) 개선된 9α-탈할로겐화 방법
DE69227478T2 (de) Neue Steroidderivate vom Typ Pregna-1,4-diene-3,20-dion, ihre Herstellung und Verwendung zur Herstellung der substituierten 16,17-Methylendioxyderivate und neuen Zwischenprodukten
SE8105686L (sv) Nya 17-oxazolin-steroidderivat, sett for framstellning derav och anvendning derav vid framstellning av kortikosteroider
DE69126622D1 (de) 2beta,19-methylenamin überbrückte steroide als aromatasehemmer
GR3021335T3 (en) New steroid derivatives of pregna-4,9(11),17(20)-trien-3-on, their preparation, their use in the preparation of derivatives of pregna-4,9(11),16-trien-3,20-dione and intermediates therefor
DE60331572D1 (de) Stereospezifische reduktion von sapogen-3-onen
DE60014096D1 (de) Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
NO944124L (no) 17 yre
ES8603910A1 (es) Procedimiento para la obtencion del ester 2-hidroxibenzoico en c-21 de un esteroide pregnanico clorado

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HOECHST MARION ROUSSEL, PUTEAUX, FR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY CEDEX, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R071 Expiry of right

Ref document number: 520879

Country of ref document: EP